White Paper

From coverage to cost-control: GLP-1 alternatives for weight loss

Sponsor Content from
Thank you for your interest. You can now access the asset below.
{download_button}


Welcome back.
You have registered as {email}. .

{download_button}

Download now

According to KFF, a nonprofit health policy research, polling, and news organization, 43% of adults in the U.S. who have been diagnosed with diabetes have tried a GLP-1. However, of the respondents to this poll, 54% of those taking a GLP-1 said it was difficult to afford, thus making cost a continuous barrier to accessing this therapy.

Employers are uniquely positioned to provide access to medication-assisted weight care—and to do so without skyrocketing costs. Download this white paper to gain insights into GLP-1 alternatives and cost-containment strategies to effectively manage the utilization and costs of this class of drugs. You will also learn more about:

Download this white paper to gain insights into:

  • Alternative anti-obesity medications (AOMs) and step therapy
  • How to establish effective GLP-1 cost-control measures
  • The importance of investing in weight care with a comprehensive approach
  • How personalization unlocks a more effective path to weight loss for patients